Drugs / AZD5991
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03218683 | Aug 2017 → Oct 2021 | acute myeloid leukemia | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-03-28 | AstraZeneca | Results Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 astrazeneca.com ↗
The first preclinical data presented on AZD5991 demonstrating the tumour cell-killing potential of this potent, selective macrocylic inhibitor of MCL-1 in blood cancers (oral presentation; Abstract #DDT01) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-03-28 | AstraZeneca | Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5991 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013998 ↗ |
| Action | Inhibit | “Mcl-1 inhibitor AZD5991” PMID 37380821 ↗ Jun 2023 |
| Modality | Small molecule | — CHEMBL4297482 ↗ |
| Route | Intravenous | “150 mg, IV, on days 1, 4, 8, 11, 15, and 18” NCT03013998 ↗ |
| Target | MCL1 | “Mcl-1 inhibitor AZD5991” PMID 37380821 ↗ Jun 2023 |